Novartis Sees Space For Sandoz But In A Slimmer Streamlined Form
Executive Summary
Sandoz has a place within Novartis as a more autonomous unit, the Swiss group’s CEO Vas Narasimhan says. But the generics and biosimilars division will have to sharpen up, aided by a 7% workforce cut.
You may also be interested in...
Saynor Seeks To Take Sandoz Back To Basics
In an exclusive interview with Generics Bulletin, Sandoz’ CEO Richard Saynor explains how he wants the Novartis division to focus on the industry basics of being first-to-market with cost-competitive generics and biosimilars.
Novartis Selects GSK’s Saynor As Next Sandoz CEO
GlaxoSmithKline’s established products head, Richard Saynor, will return to Sandoz later this year to lead the Novartis division.
Autonomous Sandoz Set To Be Tighter And Leaner
With an optimized manufacturing base, a narrower geographic footprint, and a tighter portfolio focus on differentiated biosimilars and hard-to-make generics, Novartis believes a more autonomous Sandoz division can remain an “integral part” of the Swiss group.